Treatment Clinical Trials for Breast Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for breast cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 426-447 of 447
< Previous 1 ... 16 17 18

  • Paclitaxel, Trastuzumab, and Pertuzumab with or without Pembrolizumab in Treating Patients with Metastatic Breast Cancer

    This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without pembrolizumab works in treating patients with breast cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, pertuzumab, and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel, trastuzumab, and pertuzumab with pembrolizumab may kill more tumor cells.
    Location: NRG Oncology, Philadelphia, Pennsylvania

  • A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

    The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

    The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this study is paclitaxel (WP) and carboplatin followed by doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple negative breast cancer, no additional treatment is given unless the cancer returns. This study will also look at continuing treatment after surgery with atezolizumab or the placebo. To be better, atezolizumab given with the neoadjuvant therapy should be better at: 1) decreasing the amount of tumor in the breast than the placebo given with the usual chemotherapy and 2) decreasing the chance of the cancer from returning after surgery. Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual chemotherapy. Atezolizumab may keep your cancer from growing but it can also cause side effects.
    Location: Medical University of South Carolina, Charleston, South Carolina

  • Endocrine Therapy in Treating Patients with HER2 Negative, Low Risk Breast Cancer

    This pilot phase IV trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • DNA Vaccine with or without Durvalumab in Treating Patients with Triple Negative Breast Cancer

    This randomized phase I trial studies the side effects of deoxyribonucleic acid (DNA) vaccine with or without durvalumab in treating patients with triple negative breast cancer. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells that express breast cancer. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Giving DNA vaccine with durvalumab may work better in treating patients with triple negative breast cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+ / HER2- Intermediate Risk Early Breast Cancer

    This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate risk breast cancer.
    Location: 2 locations

  • Retinoid 9cUAB30 in Producing a Biologic Effect in Patients with Early Stage Breast Cancer

    This phase Ib trial studies how well retinoid 9cUAB30 works in producing a biologic effect in patients with early stage breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of retinoid 9cUAB30 may slow disease progression in patients with early stage breast cancer.
    Location: 5 locations

  • Merestinib in Treating Patients with Breast Cancer Metastatic in the Bone

    This phase IB trial studies the side effects and best dose of merestinib in treating patients with breast cancer that has spread to the bones. Merestinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Gedatolisib and Antibody-drug Conjugate PF-06647020 in Treating Patients with Metastatic Triple Negative Breast Cancer

    This phase I trial studies the side effects of gedatolisib and antibody-drug conjugate PF-06647020 and how well they work in treating patients with triple negative breast cancer that has spread to other places in the body. Gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibody, such as antibody-drug conjugate PF-06647020, may interfere with the ability of tumor cells to grow and spread. Given gedatolisib and antibody-drug conjugate PF-06647020 may work better in treating patients with triple negative breast cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Imipramine Hydrochloride before Surgery in Treating Patients with Triple Negative Breast Cancer

    This pilot phase I / II trial studies the side effects and best dose of imipramine hydrochloride before surgery and to see how well it works in treating patients with triple negative breast cancer. Imipramine hydrochloride is a tricyclic antidepressant that may be effective in decreasing the proliferation (multiplying) rate of triple negative breast cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Stellate Ganglion Blockade with Bupivacaine Hydrochloride in Reducing Hot Flashes in Hispanic Patients with Breast Cancer

    This randomized pilot clinical trial studies how well a stellate ganglion blockade with bupivacaine hydrochloride works in reducing hot flashes in Hispanic patients with breast cancer. A stellate ganglion blockade using bupivacaine hydrochloride (a local anesthetic used to block signals at nerve endings) may help to reduce the number and severity of hot flashes in Hispanic patients with breast cancer.
    Location: Northwestern University, Chicago, Illinois

  • Neratinib and Paclitaxel with or without Pertuzumab and Trastuzumab before Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Breast Cancer

    This phase I / II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination chemotherapy in treating patients with breast cancer that has spread to other places in the body. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pertuzumab and trastuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving neratinib, pertuzumab, trastuzumab, paclitaxel and combination chemotherapy may work better in treating patients with breast cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • ErbB-2 Inhibitor ARRY-380, Palbociclib, and Letrozole in Treating Patients with Advanced or Metastatic Hormone Receptor and HER2 Positive Breast Cancer That Cannot Be Removed by Surgery

    This phase Ib / II trial studies the side effects of ErbB-2 inhibitor ARRY-380, palbociclib, and letrozole and how well they work in treating patients with in hormone receptor and HER2 positive breast cancer that has spread to other places in the body and cannot be removed by surgery. ErbB-2 inhibitor ARRY-380, palbociclib, and letrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Pembrolizumab and Ruxolitinib Phosphate in Treating Patients with Metastatic Stage IV Triple Negative Breast Cancer

    This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer.
    Location: Mayo Clinic in Arizona, Scottsdale, Arizona

  • 18F-FBnTP Positron Emission Mammography in Detecting Breast Cancer in Patients with Intraductal Breast Cancer

    This clinical trial studies how well 18F-FBnTP positron emission mammography works in detecting breast cancer in patients with intraductal breast cancer. 18F-FBnTP positron emission mammography may detect may detect breast lesions with better sensitivity and better specificity.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • TPI 287 and Fractionated Stereotactic Radiation Therapy in Treating Patients with Brain Metastases from Breast or Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of TPI 287 when given together with fractionated stereotactic radiation therapy in treating patients with breast or non-small cell lung cancer that has spread to the brain. TPI 287 may help fractionated stereotactic radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic radiation therapy delivers several small doses of radiation directly to the tumor over several days to kill and shrink tumors. Giving TPI 287 with fractionated stereotactic radiation therapy may kill more tumor cells.
    Location: Moffitt Cancer Center, Tampa, Florida

  • BRCA1 Protein Expression in Patients With Metastatic Breast Cancer Receiving Pegylated Liposomal Doxorubicin Hydrochloride

    This phase II trial studies breast cancer 1, early onset (BRCA1) protein expression in patients with metastatic breast cancer receiving pegylated liposomal doxorubicin hydrochloride. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Studying samples of tissue in the laboratory from patients receiving pegylated liposomal doxorubicin hydrochloride may help doctors learn more about the effects of BRCA1 protein expression. It may also help doctors understand how well patients respond to treatment.
    Location: The University of Arizona Medical Center-University Campus, Tucson, Arizona

  • Ruxolitinib Phosphate in Treating Patients with Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well ruxolitinib phosphate works in treating patients with breast cancer that has spread from where it started to nearby tissue or to other places in the body and that cannot be removed by surgery. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations

  • Vaccine Therapy in Treating Patients with Stage IB-IIIA Breast Cancer

    This pilot clinical trial studies the side effects of vaccine therapy in treating patients with stage IB-IIIA breast cancer. Vaccines made from peptides and immune stimulant may help the body build an effective immune response to kill tumor cells.
    Location: See Clinical Trials.gov

  • Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement

    This pilot phase II trial studies the side effects and how well cabozantinib-s-malate (cabozantinib) works alone and in combination with fulvestrant (pilot cohort) in treating patients with hormone receptor-positive breast cancer that has spread to the bone. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving cabozantinib-s-malate and fulvestrant together may be a better treatment for patients with hormone-receptor positive breast cancer.
    Location: 5 locations

  • Letrozole Before Surgery in Treating Post-Menopausal Patients With Stage I-III Hormone-Sensitive Breast Cancer That Can Be Removed By Surgery

    This clinical trial studies letrozole before surgery in treating post-menopausal patients with stage I-III hormone-sensitive breast cancer that can be removed by surgery. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery may reduce the amount of tissue that needs to be removed.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

    This phase I trial studies the side effects and best dose of buparlisib or alpelisib when given together with olaparib in treating patients with triple negative breast cancer or high grade serous ovarian cancer that has come back (recurrent). Buparlisib, alpelisib, and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: See Clinical Trials.gov


< Previous 1 ... 16 17 18